## **Product** Data Sheet

## IRAK4-IN-15

 Cat. No.:
 HY-146113

 CAS No.:
 2667681-85-6

 Molecular Formula:
 C<sub>25</sub>H<sub>29</sub>FN<sub>10</sub>

Molecular Weight: 488.56 Target: IRAK

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC $_{50}$ of 0.002 $\mu$ M. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. $^{[1]}$ .
IC <sub>50</sub> & Target	IRAK4 0.002 μM (IC <sub>50</sub> )
In Vitro	IRAK4-IN-15 (compound 35) shows cell pIRAK4 potencies with an IC <sub>50</sub> of 0.21 $\mu$ M <sup>[1]</sup> . IRAK4-IN-15 (compound 35) shows selectivity with IC <sub>50</sub> s of 0.002,1.2, >10,1.5, 0.23, 0.48, 0.93, 0.57 $\mu$ M for IRAK4, IRAK1, BTK, Flt3, PI3K $\delta$ , TRKa, TRKb, TRKc, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Degorce SL, et al. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorg Med Chem. 2020 Dec 1;28(23):115815.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA